Immunic, Inc. (NASDAQ:IMUX – Get Rating) – Equities research analysts at Wedbush raised their Q2 2023 EPS estimates for Immunic in a research note issued on Tuesday, May 16th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.45) per share for the quarter, up from their previous forecast of ($0.49). Wedbush has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($2.13) per share. Wedbush also issued estimates for Immunic’s Q3 2023 earnings at ($0.43) EPS, Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at ($1.89) EPS, FY2024 earnings at ($1.71) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($1.78) EPS and FY2027 earnings at ($1.83) EPS.
Immunic (NASDAQ:IMUX – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.81).
Immunic Price Performance
Shares of NASDAQ:IMUX opened at $1.77 on Thursday. Immunic has a 1-year low of $1.11 and a 1-year high of $11.76. The company has a market capitalization of $78.59 million, a P/E ratio of -0.49 and a beta of 1.86. The firm’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.64.
Hedge Funds Weigh In On Immunic
Several hedge funds have recently modified their holdings of the stock. RTW Investments LP lifted its holdings in shares of Immunic by 11.2% in the first quarter. RTW Investments LP now owns 4,294,459 shares of the company’s stock worth $6,399,000 after buying an additional 433,169 shares in the last quarter. Gratus Capital LLC lifted its holdings in shares of Immunic by 121.5% in the fourth quarter. Gratus Capital LLC now owns 1,668,294 shares of the company’s stock worth $2,336,000 after buying an additional 915,104 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Immunic by 0.9% in the first quarter. BlackRock Inc. now owns 1,314,484 shares of the company’s stock worth $14,853,000 after buying an additional 11,708 shares in the last quarter. Artal Group S.A. raised its stake in Immunic by 82.1% during the fourth quarter. Artal Group S.A. now owns 1,274,713 shares of the company’s stock valued at $1,785,000 after purchasing an additional 574,713 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Immunic by 13.2% during the third quarter. Vanguard Group Inc. now owns 994,671 shares of the company’s stock valued at $3,143,000 after purchasing an additional 115,649 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856.
Read More
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
